

| | Survivor n=142 | Sibling controls n=75 |
|--|---------------------------|----------------------------------|
| Cumulative doxorubicin dose categories | | NA |
| <250 mg/m ² | 13 (9.2%) | |
| 250-300 mg/m ² | 40 (28.2%) | |
| >300 mg/m ² | 89 (62.7%) | |
| Mediastinal radiotherapy | 38 (26.7%) | NA |
| Stem cell transplantation | 17 (12.1%) | NA |
| Cardiovascular risk factors | | |
| Diabetes Mellitus | 7 (4.9%) | 3 (4.0%) |
| Hypertension | 57 (40.1%) | 29 (38.7%) |
| Hypercholesterolemia | 40 (28.2%) | 18 (24.0%) |
| High BMI (>25) | 83 (58.5%) | 36 (48.0%) |
| Smoking | | |
| Never | 69 (48.6%) | 37 (49.3%) |
| Former | 52 (36.6%) | 24 (32.0%) |
| Current | 13 (9.2%) | 13 (17.3%) |
| Unknown | 8 (5.6%) | 1 (1.3%) |
| LVEF category | | |
| ≤40% | 7 (4.9%) | 2 (2.7%) |
| 40.1-49% | 24 (16.9%) | 5 (6.7%) |
| 50-54% | 41 (28.9%) | 15 (20.0%) |
| ≥55% | 70 (49.3%) | 53 (70.7%) |
| GLS category | | |
| Normal (≤-18%) | 57 (40.1%) | 40 (53.3%) |
| Impaired (>-18%) | 59 (41.6%) | 25 (33.3%) |
| Missing | 26 (18.3%) | 10 (13.3%) |
| NT-proBNP category | | |
| Normal (<125 pg/mL) | 77 (54.2%) | 65 (86.7%) |
| Increased (≥125 pg/mL) | 59 (41.5%) | 8 (10.7%) |
| Missing | 6 (4.2%) | 2 (2.7%) |